A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC0902).
Masaaki Takeuchi
No relevant relationships to disclose
Yutaka Ogata
No relevant relationships to disclose
Takaho Tanaka
No relevant relationships to disclose
Atsushi Kaibara
No relevant relationships to disclose
Yasunori Emi
No relevant relationships to disclose
Hiroshi Saeki
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Noriaki Sadanaga
No relevant relationships to disclose
Tetsuya Kusumoto
No relevant relationships to disclose
Tetsuo Touyama
No relevant relationships to disclose
Hiroo Matsushita
No relevant relationships to disclose
Mototugu Shimokawa
No relevant relationships to disclose
Hideo Baba
No relevant relationships to disclose
Kazuo Shirouzu
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Chugai Pharma; Yakult Honsha